Novartis Projects OTC Return By Summer, Expects Flat Sales In 2012
By
Dan Schiff / Email the Author / “The Tan Sheet” Jan. 30, 2012, Vol. 20, No. 05
OTCs / Word Count: 395 / Article # 05120130022
Executive Summary
Novartis’ 2012 guidance conservatively assumes the offline OTC facility in Lincoln, Neb., will return to production by mid-year, CEO Joseph Jimenez says. The firm halted shipments of Excedrin and other OTCs from Lincoln in December, and consumer health sales fell 7.3% in the fourth quarter.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.